Tag: pharmaceuticals

  • European Commission Approval Granted for Blood Pressure Drug

    The pharmaceutical company Novartis in Basel, Switzerland says its drug Rasitrio has received approval from the European Commission (EC) for the treatment of hypertension or high blood pressure. The drug was designed for blood pressure patients who need multiple medications to treat their condition. Rasitrio has the compound Rasilez, an inhibitor of the enzyme renin…

  • Commentary: Manufacturing the Health Care Venture Crisis

    Rahm Emanuel, the current mayor Chicago and former chief of staff to President Obama, once famously said, “You never want a serious crisis to go to waste.” The National Venture Capital Association (NVCA) has gone Emanuel one better, using highly selected bits and pieces from an industry survey to predict an imminent retreat by investors…

  • University Awarded U.S. Patent for HPV Discovery

    The U.S. Patent and Trademark Office has granted a patent to University of Rochester in New York for research conducted on the human papillomavirus virus (HPV). The research by Rochester virologists Robert Rose, Richard Reichman, and William Bonnez led to development of vaccines now used to prevent cervical and other cancers caused by HPV. The…

  • MedImmune, Univ. of Michigan to Partner on Biologics

    University of Michigan Medical School in Ann Arbor and MedImmune in Gaithersburg, Maryland have agreed to collaborate on research leading to new biologic therapies for a range of diseases. MedImmune is the biologics division of the global pharmaceutical company AstraZeneca. Biologics are treatments or therapies developed through biological processes, such as genes or cellular products,…

  • Process Developed for Delivering Appetite Control Hormone

    Researchers at Syracuse University in New York and Murdoch University in Australia have devised a method for binding an appetite-suppressing hormone to vitamin B12, a key step needed for delivering the hormone in gum or tablet form. Their process is described online in the Journal of Medicinal Chemistry (paid subscription required). Syracuse chemistry professor Robert…

  • Gilead Sciences to Acquire Biotech Pharmasset for $11B

    Pharmaceutical maker Gilead Sciences in Foster City, California says it will acquire the biotechnology company Pharmasset Inc. in Princeton, New Jersey, with the transaction expected to close in the first quarter of 2012. In the deal, Gilead will pay $137 per share, for a total value of about $11 billion. Pharmasset is a clinical-stage company…

  • FDA Approves Age-Related Macular Degeneration Drug

    The Food and Drug Administration approved the drug Eylea (aflibercept) to treat patients with neovascular age-related macular degeneration (AMD), also known as “wet” AMD. Regeneron Pharmaceuticals Inc. in Tarrytown, New York developed Eylea, in partnership with Bayer HealthCare in Germany. Wet AMD is a leading cause of vision loss and blindness in Americans ages 60…

  • Scripps, Biotech to Partner on Feline Virus Research

    CytoDyn Inc., a biotechnology company in Lutz, Florida, has agreed to support research by Spripps Research Institute scientist John Elder on the company’s treatment for feline immunodeficiency virus (FIV). Elder is a professor in Scripps’s Department of Immunology and Microbial Science in La Jolla, California. Under the agreement CytoDyn’s subsidiary, CytoDyn Veterinary Medicine LLC will…

  • Treatment for Rare Bone Marrow Disease Gains FDA Approval

    The Food and Drug Administration today approved the drug ruxolitinib, to treat the bone marrow disease myelofibrosis, for marketing in the U.S. Ruxolitinib is marketed under the brand name Jakafi by Incyte Corporation, a biotechnology company in Wilmington, Delaware. Jakafi is a pill taken two times a day to inhibit enzymes called Janus Associated Kinase…

  • Biotech Start-Up Lands $15M Series A Round

    Allena Pharmaceuticals Inc. in Newton, Massachusetts, a biotechnology start-up company, says it has secured $15 million in Series A venture capital financing, the first round of funding after seed capital. The company was founded by Alexey Margolin and Robert Gallotto, former executives at Alnara Pharmaceuticals that was acquired by Eli Lilly and company in July…